Breast and endometrial safety of micronised progesterone versus norethisterone acetate in menopausal hormone therapy (PROBES): study protocol of a double-blind randomised controlled trial.

Autor:	Lundell C; Karolinska Institutet, Stockholm, Sweden., Stergiopoulos N; Karolinska Institutet, Stockholm, Sweden., Blomberg L; Karolinska Institutet, Stockholm, Sweden., Ujvari D; Karolinska Institute, Solna, Sweden., Schuppe-Koistinen I; Karolinska Institutet, Stockholm, Sweden., Kopp-Kallner H; Karolinska Institutet, Stockholm, Sweden., Iliadis SI; Women's and Children's Health, Uppsala University, Uppsala, Sweden., Skalkidou A; Uppsala University, Uppsala, Sweden., Hirschberg AL; Karolinska Institutet, Stockholm, Sweden Angelica.Hirschberg.Linden@ki.se.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2024 Oct 23; Vol. 14 (10), pp. e082749. Date of Electronic Publication: 2024 Oct 23.
DOI:	10.1136/bmjopen-2023-082749
Abstrakt:	Introduction: Data suggest that micronised progesterone (mP) in menopausal hormone therapy is safer for the breast than synthetic progestins, while protection of the endometrium appears to be less effective. However, comparative randomised trial data are lacking. The objective of the Progesterone Breast Endometrial Safety Study is to investigate breast and endometrial safety of mP versus norethisterone acetate (NETA) in continuous combination with oral oestrogen. Methods and Analysis: This multicentre trial, conducted at three University Hospitals in Stockholm and Uppsala, Sweden, consists of two phases: part 1 focuses on breast safety and is designed as a double-blind, randomised controlled trial. 260 postmenopausal women will be randomised to 100 mg mP or 0.5 mg NETA per day in continuous combination with 1 mg oestradiol. The primary objective is to compare the treatments with respect to percentage change in mammographic breast density after 12-month treatment. Secondary outcomes are breast proliferation, endometrial histology and proliferation, bleeding pattern, gut and vaginal microbiome, hormone levels and coagulation and metabolic factors, mood, and health-related quality of life. Part 2 features an open, single-arm design to study endometrial safety of 1-year treatment with mP in continuous combination with oestradiol on endometrial pathology (hyperplasia and cancer). We will treat 260 additional women with 100 mg mP/1 mg oestradiol resulting in an endometrial safety population of 390 women. The total number of participants in part 1 and part 2 will be 520. Ethics and Dissemination: The study protocol was approved by the Swedish Ethical Review Authority (2021-03033) on 29 June 2021 with amendment (2023-01480-02, protocol version 3.1) on 14 March 2023. Results of the study will be published in peer-reviewed journals and presented at scientific meetings. Trial Registration Number: NCT05586724. Competing Interests: Competing interests: This is an investigator-initiated study. The company Besins healthcare Ireland has provided financial support and study medication but has not been involved in the preparation of the study protocol and will not be involved in the evaluation and publication of study results. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu